Recombinant Lloviu virus as a tool to study viral replication and host responses

Adam J. Hume, Baylee Heiden, Judith Olejnık, Ellen L. Suder, Stephen Ross, Whitney A. Scoon, Esther Bullitt, Maria Ericsson, Mitchell R. White, Jacquelyn Turcincovic, Tran T. N. Thao, Ryan M. Hekman, Joseph E. Kaserman, Jessie Huang, Konstantinos-Dionysios Alyandratos, Gabor E. Toth, Ferenc Jakab, Darrell N. Kotton, Andrew A. Wilson, Andrew Emini, Volker Thiel, John H. Connor, Gabor Kemenesi, Daniel Cifuentes, Elke Mühlberger

1 Department of Microbiology, Boston University School of Medicine; Boston, Massachusetts, United States of America, 2 National Emerging Infectious Diseases Laboratories, Boston University; Boston, Massachusetts, United States of America, 3 Department of Biochemistry, Boston University School of Medicine; Boston, Massachusetts, United States of America, 4 Department of Physiology & Biophysics, Boston University School of Medicine; Boston, Massachusetts, United States of America, 5 Department of Cell Biology, Harvard Medical School; Boston, Massachusetts, United States of America, 6 Program in Bioinformatics, Boston University; Boston, Massachusetts, United States of America, 7 Institute of Virology and Immunology (IVI); Bern, Switzerland, 8 Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern; Bern, Switzerland, 9 Center for Network Systems Biology, Boston University; Boston, Massachusetts, United States of America, 10 Center for Regenerative Medicine of Boston University; Boston, Massachusetts, United States of America, 11 The Pulmonary Center and Department of Medicine, Boston University School of Medicine; Boston, Massachusetts, United States of America, 12 Institute of Biology, Faculty of Sciences, University of Pécs, Pécs, Hungary, 13 Szentágothai Research Centre, University of Pécs; Pécs, Hungary, 14 Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston Medical Center; Boston, Massachusetts, United States of America, 15 Department of Biology, Boston University; Boston, Massachusetts, United States of America

* hume@bu.edu (AJH); muehlber@bu.edu (EM)

Abstract

Next generation sequencing has revealed the presence of numerous RNA viruses in animal reservoir hosts, including many closely related to known human pathogens. Despite their zoonotic potential, most of these viruses remain understudied due to not yet being cultured. While reverse genetic systems can facilitate virus rescue, this is often hindered by missing viral genome ends. A prime example is Lloviu virus (LLOV), an uncultured filovirus that is closely related to the highly pathogenic Ebola virus. Using minigenome systems, we complemented the missing LLOV genomic ends and identified cis-acting elements required for LLOV replication that were lacking in the published sequence. We leveraged these data to generate recombinant full-length LLOV clones and rescue infectious virus. Similar to other filoviruses, recombinant LLOV (rLLOV) forms filamentous virions and induces the formation of characteristic inclusions in the cytoplasm of the infected cells, as shown by electron microscopy. Known target cells of Ebola virus, including macrophages and hepatocytes, are permissive to rLLOV infection, suggesting that humans could be potential hosts. However, inflammatory responses in human macrophages, a hallmark of Ebola virus disease, are not induced by rLLOV. Additional tropism testing identified pneumocytes as capable of robust rLLOV and Ebola virus infection. We also used rLLOV to test antivirals targeting multiple
Author summary

Due to increasing utilization of high-throughput sequencing technologies, RNA sequences of many unknown viruses have been discovered in bats and other animal species. Research on the pathogenic potential of these viruses is hampered by incomplete viral genome sequences and difficulties in isolating infectious virus from the animal hosts. One example of these potentially zoonotic pathogens is Lloviu virus (LLOV), a filovirus which is closely related to Ebola virus. Here we applied molecular virological approaches, including minigenome assays, to complement the incomplete LLOV genome ends with sequences from related viruses and identify cis-acting elements required for LLOV replication and transcription that were missing in the published LLOV sequence. The resulting full-length clones were used to generate infectious recombinant LLOV. We used this virus for electron microscopic analyses, infection studies in human cells, host response analysis, and antiviral drug testing. Our results provide new insights into the pathogenic potential of LLOV and delineate a roadmap for studying uncultured viruses.

Introduction

Zoonotic viruses are a major public health threat. A single spillover event from an animal host into the human population can initiate deadly epidemics or even pandemics. Bats play an important role as natural reservoirs of RNA viruses with the potential to cause significant harm to humans. Examples of bat-borne viruses that have been transmitted to humans, either directly or via intermediate hosts, causing multiple epidemics include Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), Hendra virus, Nipah virus, and Marburg virus (MARV). For other viruses, such as Middle East Respiratory Syndrome coronavirus (MERS-CoV), pandemic SARS-CoV-2, and Ebola virus (EBOV), there is strong evidence that bats might be the natural reservoir, although these viruses have not yet been isolated from bats [1]. While some of these represent reemerging viruses that were already known to cause severe disease in humans, this list also includes a number of bat-borne viruses that were either unknown or understudied prior to spillover into the human population.

To better prepare for potential future zoonotic epidemics and pandemics, it is necessary to study newly discovered viruses that are closely related to highly pathogenic viruses to both determine their pathogenic potential and to develop and assess potential antiviral therapies. Since 2000, multiple new filoviruses have been discovered via next generation sequencing of samples from wild bats across the globe, including Lloviu virus (LLOV), Bombali virus, and Mengla virus [2–4], but the ability to study these viruses has been limited because none of these new viruses have been cultured to date.

One particular virus of concern is LLOV, a filovirus whose viral RNA was initially isolated from carcasses of Schreiber’s bats (Miniopterus schreibersii) in Spain and France using deep sequencing and PCR techniques and later found in the same species of bats in Hungary, although no infectious virus has been cultured to date [2,5,6]. Recently, LLOV re-emerged in bat populations in Northeast Hungary, and again its emergence correlated with unexplained increased mortality among Schreiber’s bats [5]. Interestingly, many of the bats in which LLOV RNA was found showed symptoms of respiratory infection, but it remains to be determined if LLOV is the causative agent of the disease [2,5]. One worrying factor regarding the spillover...
potential for LLOV is the geographic range of the host species, *Miniopterus schreibersii*, which can be found across most of southern Europe, parts of northern Africa, and much of the Middle East, in which over 100 million people live. At the sequence level, LLOV is distinct enough from the ebola- and marburgviruses to be classified within its own genus *Cuevavirus* [7]. Although the pathogenic potential of LLOV remains unknown, similarities to EBOV and MARV raise concerns that it could be pathogenic for humans. However, the pathogenicity of filoviruses varies considerably, highlighting the need to study LLOV in more detail.

Like many of the genomic sequences of these other uncultured RNA viruses, the LLOV genome is incomplete [2]. The lack of the terminal genomic sequences that orchestrate viral transcription and replication makes development of a fully wild-type reverse genetic system to rescue the virus impossible. Here we describe the complementation of the LLOV sequence with terminal genomic sequences from other filoviruses in mono- and bicistronic minigenome systems to determine the ability of these sequences to facilitate different aspects of the LLOV replication cycle. Leveraging the data from these complementation assays, we were able to develop a reverse genetic system that facilitated the rescue of infectious recombinant Lloviu virus complemented with sequences from EBOV or MARV (rLLOV_comp). We analyzed rLLOV_comp in various assays, ranging from ultrastructural analysis of infected cells to infection studies with primary human cells, antiviral testing, and host response analysis. Our data suggest that LLOV has the potential to infect humans but does not induce an inflammatory response in human macrophages, a hallmark of severe Ebola virus disease [8]. The success of this approach provides a roadmap for the rescue and characterization of other uncultured RNA viruses of pathogenic concern for which we currently only have incomplete genomic sequences.

**Results and discussion**

**Complementation assays to identify functional 5′ genomic ends for LLOV**

As a member of the filovirus family, LLOV has a nonsegmented negative sense RNA genome. The published LLOV genome sequence lacks four 3′ terminal nucleotides and almost the entire trailer region. Since the replication and transcription promoter regions of negative sense RNA viruses are contained within the genome ends, called the leader and trailer regions, the lack of the terminal sequences has hampered the generation of recombinant LLOV clones and viral rescue. We previously showed that chimeric LLOV minigenomes that utilize the LLOV leader complemented with four 3′ terminal EBOV nucleotides in combination with the poly-A polymerase (L) gene 5′ noncoding region (encoding the 3′ UTR of the L mRNA) and trailer regions (UTR+tr) of EBOV, RESTV, and MARV are each replication and transcription competent [9]. To identify a potent chimeric trailer region for use in full-length rLLOV_comp clones, we generated LLOV minigenomes containing the complete LLOV 5′ noncoding region including the sequence encoding the L 3′ UTR and the 8 known nucleotides of the LLOV trailer complemented with varying lengths of 5′ terminal sequences of the EBOV Mayinga genome (Fig 1A). Minigenomes with these chimeric LLOV-EBOV 5′ ends were functional, with a general trend of the shorter hybrid trailers being less active (Figs 1B and S1). Of note, some of these LLOV minigenomes with chimeric trailers were more active than the LLOV minigenome utilizing the full 5′ end of EBOV (EBOV_UTR+tr, Figs 1B and S1).

**Full-length LLOV clones containing bicistronic VP24-L genes cannot be rescued**

Based on the minigenome data, we successfully generated full-length LLOV clones that contained the EBOV_UTR+tr, MARV_UTR+tr, or LE72 as 5′ genome ends. LE72 genome ends were
chosen because this minigenome performed best in the minigenome assay (Figs 1B and S1).

Since there are no commercially available antibodies against LLOV and we detected no cross-reactivity with LLOV proteins using antibodies against other filoviruses, we also constructed these rLLOV\textsubscript{comp} full-length clones with the addition of a ZsGreen reporter attached to the VP40 gene via a P2A sequence as previously described for EBOV [10]. Viral rescue was attempted by transfecting cocultures of African green monkey kidney (Vero E6) and human hepatocarcinoma (Huh7) cells with full-length clone rLLOV\textsubscript{comp} plasmids along with codon-optimized LLOV support plasmids as previously described for the LLOV minigenome system [9]. However, repeated attempts to rescue these clones were unsuccessful (S2 Fig). One striking observation regarding the published LLOV genomic sequence is the lack of gene end (GE) and gene start (GS) signals within the VP24-L intergenic region (IR), which has led to speculation that these genes may be expressed bicistronically [2]. However, this would be unique, as there are, to our knowledge, no instances of bicistronic or polycistronic genes for any nonsegmented negative sense RNA viruses outside of the bornavirus family [11,12]. To test whether this lack of GE and GS signals might play a role in the expression of both the LLOV VP24 and L genes, we constructed and tested a bicistronic minigenome that included the wild-type LLOV VP24-L IR between firefly and renilla luciferase reporter genes (Fig 1C). Although we saw expression of the first reporter gene in a minigenome assay, expression of the second gene was not observed (Fig 1D). The addition of conserved LLOV GE and GS signals within this IR in the bicistronic minigenome (IR\textsubscript{ins}), however, facilitated efficient expression of both reporter genes, indicating that there is a strict requirement for flanking GS and GE signals for each LLOV gene (Fig 1D).

Rescue and characterization of recombinant Lloviu viruses

Incorporation of the VP24-L IR\textsubscript{ins} sequence into rLLOV\textsubscript{comp} full-length genomes facilitated the rescue of three different versions of rLLOV\textsubscript{comp} containing the ZsGreen-P2A-VP40
The ability of these viruses to be rescued only with the addition of the IR\textsubscript{ins} sequence further highlights the strict functional need for GS and GE sequences within the LLOV genome. This raises questions about whether the published LLOV VP24-L IR\textsubscript{ins} sequence is potentially incomplete, possibly due to masking of IR\textsubscript{ins} sequences on the viral genome by abundant viral mRNA or due to possible sequencing difficulty caused by RNA secondary structures. However, since the sequencing files from the original discovery of LLOV are not publicly available, these hypotheses cannot be assessed [2].

We next sought to compare replication kinetics of rescued Lloviu viruses with recombinant EBOV (Mayinga) and RESTV (Pennsylvania) containing ZsGreen-P2A-VP40 reporters in three different cell lines. All three rLloviu viruses grew to lower titers in Vero E6 cells, a cell line frequently used for filovirus replication kinetics, and replicated more slowly than both the rEBOV and rRESTV, with rLLOV-LE\textsubscript{72} representing the slowest-growing virus (Fig 2B). Similar patterns of growth kinetics were observed in Huh7 cells and in the bat (M. schreibersii) kidney cell line SuBK12-08 [13] using two different initial multiplicities of infection (MOIs), with the notable exception that rRESTV grew comparatively slower in the bat cells (Figs 2C, 2D and S3). While Vero E6 and SuBK12-08 cells can be kept in culture without passaging for up to two weeks without showing cytopathic effects, Huh7 cells require passaging after 4–5 days, explaining the shorter incubation period for the Huh7 cells in this experiment. Proteomic analysis of SuBK12-08 cells infected with rLLOV-IR\textsubscript{ins}-MARV\textsubscript{UTR+tr} at a multiplicity of infection (MOI) of 1 at two days post-infection (dpi). Signal intensities of viral proteins are plotted relative to L signal intensity within the same sample. (F) RNA FISH analysis of Vero E6 cells infected with rLLOV-IR\textsubscript{ins}-MARV\textsubscript{UTR+tr} at an MOI of 1 at 1 dpi. Red, negative sense genomic LLOV RNA clustered in viral inclusions. Cell nuclei were stained with DAPI (blue).

https://doi.org/10.1371/journal.ppat.1010268.g002

reporter, EBOV\textsubscript{UTR+tr}, MARV\textsubscript{UTR+tr}, and LE\textsubscript{72} (Figs 2A and S2). The ability of these viruses to be rescued only with the addition of the IR\textsubscript{ins} sequence further highlights the strict functional need for GS and GE sequences within the LLOV genome. This raises questions about whether the published LLOV VP24-L IR sequence is potentially incomplete, possibly due to masking of IR\textsubscript{ins} sequences on the viral genome by abundant viral mRNA or due to possible sequencing difficulty caused by RNA secondary structures. However, since the sequencing files from the original discovery of LLOV are not publicly available, these hypotheses cannot be assessed [2].
the transcriptional gradients observed in EBOV and MARV infections [14]. The published LLOV sequence contains a hypothetical open reading frame predicted to be encoded on the antigenome overlapping the VP24 gene (rcORF, GenBank: JF828358.1, “hypothetical protein”, complement(10572..11141)). However, there are no GS or GE signals flanking this ORF and there are no published reports of any filoviruses having the ability to transcribe from the antigenome. Proteomic analysis did not indicate any evidence for the expression of this rcORF.

Vero E6 cells infected with rLLOV_comp showed typical filoviral inclusions by RNA fluorescence in situ hybridization (FISH) analysis, as visualized by clustered localization of viral genomic RNA (Fig 2F). Similarly, infection of both human (Huh7) and bat (SuBK12-08) cells with rLLOV_comp showed characteristic filovirus inclusions by ultrastructural analysis, with both transverse and longitudinal sections of filamentous nucleocapsids visualized by electron microscopy (EM), similar to filovirus inclusions [15] (Figs 3A–3D and S5). Lloviu virions were observed budding from infected cells (Fig 3C; see S5A–S5C Fig for EBOV budding). We also examined rLLOV_comp particles by both transmission electron microscopy and cryoelectron microscopy, observing typical filoviral virion morphologies including filamentous and 6-shaped particles, filamentous particles with terminal membrane protrusions, and branched filamentous particles (Fig 3F and 3G), similar to EBOV virion morphologies (S5D Fig).

RNA-Seq analysis of the rLLOV_comp stocks indicated few changes, with limited single nucleotide variants identified (S6 Fig). No consensus changes were observed in any of the filovirus proteins that have previously been identified to play a role in antiviral responses or cross-species adaptation, including VP35, VP40, glycoprotein (GP), and VP24 [16] (S6 Fig). Additionally, after high-throughput cloning and sequencing of the 5’ terminal genomic sequences of the rLLOV-EBOV_UTR+tr and -MARV_UTR+tr stocks we observed very few changes in the 5’
terminal sequences of either of these viruses. These changes were all detected at low abundance despite good sequencing coverage, with the exception of an untemplated AC dinucleotide at the 5' terminal end of the rLLOV-EBOV_{UTR+tr} sequence found in about 20% of sequence reads (S7 Fig and S1 Dataset). The relative lack of mutations at the 5' end of these viruses indicates that the LLOV polymerase has some flexibility in promoter recognition.

To gain insight into LLOV host cell tropism, we compared the ability of rLLOV\textsuperscript{comp} and rEBOV to infect two key target cell types during filovirus infections in humans, macrophages and hepatocytes [17]. Both monocyte-derived macrophages (MDMs) and induced pluripotent stem cell (iPSC)-derived, primary-like hepatocytes (iHeps) [18] were permissive to infection with rLLOV\textsuperscript{comp} and rEBOV (Fig 4A and 4B). These data indicate that there is no species or cell-type tropism block that would prevent LLOV from being able to productively infect human cells.

Since some of the Schreiber’s bats identified during LLOV-associated die-offs showed lung infiltrates [2,5], we also tested the ability of these viruses to infect iPSC-derived human alveolar type 2 cells (iAT2s) [19,20], an important lung cell type which had never been previously analyzed in the context of filovirus infections. Both rEBOV and rLLOV\textsuperscript{comp} were able to infect these cells efficiently, with rapid virus spread (Fig 4C). Although filovirus infections in humans have not been associated with aerosol spread, the lung is a target organ of EBOV infection in humans as shown by pulmonary histopathology of fatal EBOV disease cases [17]. In addition, EBOV infection through the aerosol route has been demonstrated in nonhuman primates [21]. EBOV and RESTV infections of pigs were associated with lung pathology and oronasal shedding of viral particles [22,23], indicating that there might be host and virus species specific differences in filoviral pathogenesis and transmission routes.

Use of rLLOV\textsuperscript{comp} to test the efficacy of potential therapeutics

One highly useful application for recombinant viruses such as rLLOV\textsuperscript{comp} that are rescued with the aid of complementation with small non-coding terminal sequences from closely related viruses is the ability to study the effects of antiviral compounds on a highly authentic replication-competent virus. Comparing rLLOV\textsuperscript{comp} and rEBOV in both human and bat cells, we found similar inhibition of each virus in both cell types by remdesivir (Figs 5A and S8), a
nucleoside analog known to inhibit EBOV RNA synthesis [24], confirming recently published results using a LLOV minigenome system [25]. Parallel analysis using U18666A, an inhibitor of the filovirus receptor Niemann-Pick C1 (NPC1) previously shown to inhibit EBOV entry [26,27], also showed inhibition of both viruses in both cell types (Figs 5B and S8), which is in line with previous results indicating that LLOV uses NPC1 to mediate cell entry [28]. rLLOV comp was slightly more sensitive to universal type I IFN pre-treatment than rEBOV, particularly in human cells (Figs 5C and S8). Conversely, while mAb114 (brand name Ebanga), a neutralizing monoclonal antibody targeting EBOV GP and approved for treatment of EBOV disease [29], effectively blocked rEBOV infection in a dose-dependent manner at concentrations similar to those previously published [29], it had no effect on rLLOV comp replication (Fig 5D and S8). This corroborates previous studies showing that pan-ebolavirus anti-GP antibodies did not block entry of vesicular stomatitis virus pseudotyped with LLOV GP [30], emphasizing the requirement of designing antivirals tailored to the virus of interest. In summary, rLLOV comp can be used to test all steps of the viral replication cycle, including entry, viral RNA synthesis, assembly, and egress, as potential targets for antiviral therapeutics using a single system.

**Use of rLLOV comp for host response analysis**

A hallmark of severe EBOV infection is an exacerbated inflammatory response characterized by the induction of interferon-stimulated genes and proinflammatory modulators [8]. This inflammatory response is likely driven by activated monocytes and macrophages [31]. We previously compared the host response to infection with the highly pathogenic EBOV and the less pathogenic RESTV in human MDMs and observed a strong upregulation of type I IFN and proinflammatory responses in EBOV-infected MDMs, whereas RESTV-infected MDMs remained mainly silent [32]. To explore whether rLLOV comp would induce an EBOV- or RESTV-like host response in macrophages, MDMs obtained from 3 donors were infected with EBOV, RESTV, or rLLOV comp, at an MOI of 10. RNA-FISH analysis demonstrated the presence of viral genome and transcripts for all viruses with minimal background staining observed in mock-infected cells (Figs 6A and S9), yet variable infection rates were observed, with a trend of rLLOV comp having infection rates similar to, or higher than, EBOV and RESTV. However, rLLOV comp infections generally appeared to be in an earlier stage of infection as evidenced by less abundant positive and negative sense viral RNA (Figs 6A and S10). Infection rates also varied between donors (Fig 6A). Typical filoviral inclusions within the cytoplasm of the infected MDMs were observed for all
viruses as visualized by viral RNA clusters, particularly with viral genomic RNA, indicating robust viral replication in these cells (Fig 6B).

Transcriptional analysis of select genes confirmed previously observed responses to EBOV and RESTV infection [32]. While we observed robust upregulation of CXCL10 and IFNβ and, to a lesser extent, upregulation of IL6 and IL8 in EBOV-infected cells, there was only modest or no upregulation of the target genes in RESTV- and rLLOV-comp-infected cells, suggesting that similar to RESTV, rLLOV-comp does not activate human MDMs (Fig 6C).

Unstudied zoonotic viruses, particularly those closely related to known human pathogens, pose a threat of spillover with the potential to cause epidemics and pandemics within the human population. While many such RNA viruses, including filoviruses, have recently been discovered by unbiased sequencing technologies such as RNA-Seq [2–4], the coverage of their genomes is typically incomplete due to missing genomic terminal sequences. Here we provide a blueprint for studying uncultured, potentially pathogenic viruses that currently only exist as incomplete sequences using LLOV, a filovirus, as an example. We used noncoding terminal sequences from other filoviruses to complement the missing LLOV sequence and we also discovered that an intergenic region lacking conserved gene start and gene end signals was non-functional. We leveraged the data from these complementation assays to rescue recombinant LLOV. Using rLLOV-comp, we show that there are no restrictions for LLOV infection of human cells, including primary targets of pathogenic filovirus infections such as macrophages and hepatocytes [17,33], seemingly indicating that spillover of LLOV to humans may be possible. While the molecular mechanisms of filovirus pathogenicity still remain elusive, previous
studies have hypothesized that slower replication kinetics and muted inflammatory responses with RESTV play a role in the virus being likely nonpathogenic to humans [32,34,35]. Similarly, LLOV replicates slowly and does not activate MDMs, potentially pointing to LLOV not being pathogenic in humans. Therefore, based on our data with rLLOVcomp, it appears that LLOV may have a RESTV-like phenotype, having the capacity to infect humans but lacking the ability to cause disease [36].

Particularly when trying to answer questions regarding potential pathogenicity, recombinant viruses overcome limitations of other tools that analyze only isolated steps of viral replication, such as viral genome replication and transcription (minigenome assays) or viral entry (virus-like particles) [37]. Recombinant viruses allow for a plethora of studies to address questions of potential spillover and pathogenicity, including tropism studies, analyzing host responses of primary target cells, and ultimately animal infection studies. Additionally, recombinant viruses are perfectly suited to high throughput drug screens, since they are cheaper, more scalable, and subject to fewer confounding factors such as transfection efficiency that are associated with model systems. The addition of reporter genes and use of RNA-based detection assays are also particularly beneficial for this and other purposes since reagents such as antibodies to detect these novel viruses may not be available.

One limitation to using recombinant viruses with complemented genomic termini is that these exogenous sequences could be suboptimal, making these viruses replicate more slowly and to lower titers. It was therefore surprising that we did not observe substantial sequence changes within the trailer region in the rLLOVcomp stocks, suggesting some flexibility of the viral polymerase complex in recognizing promoter elements.

Materials and methods

Biosafety statement

All work with wildtype and recombinant EBOV, RESTV, and LLOV was performed in the biosafety level 4 (BSL-4) facility of Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) following approved standard operating procedures in compliance with local and national regulations pertaining to handling BSL-4 pathogens and Select Agents.

Cell lines

Cell lines used in this study include human embryonic kidney cells (293T; ATCC CRL-3216), African green monkey kidney cells (Vero E6; ATCC CRL-1586), human liver cells (Huh7; kindly provided by Apath L.L.C.), Miniopterus schreibersii kidney cells (SuBK12-08; kindly provided by Ayato Takada, Hokkaido University) [13], and golden hamster baby kidney cells (BHK-21; ATCC CCL-10). 293T, Vero E6, and Huh7 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine (200 mM), and either penicillin (50 units/ml) and streptomycin (50 mg/ml) or 100 ug/ml Primocin. BHK-21 cells were maintained in Glasgow’s Minimum Essential Medium (G-MEM) supplemented with 10% FBS, L-glutamine (200 mM), and 2% MEM amino acid solution (50x). SuBK12-08 were grown in Advanced RPMI 1640 supplemented with 10% FBS, 2% MEM amino acid solution (50x), sodium pyruvate (110 mg/L), and 100 ug/ml Primocin. All cell lines were grown at 37˚C/5% CO2.

Generation of macrophages

Monocyte-derived macrophages (MDMs) were generated as described previously [32]. Briefly, MDMs were generated from Leukoreduction system (LRS) chambers (NY Biologics Inc.)
using Ficoll separation (GE Healthcare) and isolation of CD14+ monocytes by magnetic bead selection (Miltenyi Biotec). CD14-selected cells were seeded into ultra-low attachment 6-well plates (Corning) for differentiation into MDMs using RPMI medium supplemented with penicillin (50 units/ml), streptomycin (50 mg/ml), HEPES (10 mM), 5% FBS (certified One Shot, Gibco) supplemented with 100 ng/mL human GMCSF (Peprotech) for 6–8 days. Differentiated MDMs were lifted from plates using Cell Stripper (Corning), and 2x10^5 cells were seeded into 24-well culture plates or 5x10^4 cells into Lab-Tek II 8-well chamber slides (Nunc/Thermo Fisher). To account for donor variations, experiments were performed with cells obtained from at least three different donors as noted in the figure legends. Throughout the figures, each donor is represented by a donor-specific symbol.

**Induced pluripotent stem cell (iPSC) culture and directed differentiation into hepatocytes**

The human induced pluripotent stem cell (iPSC) line “BU3” was maintained as described previously [38]. Briefly, the iPSC line was maintained in feeder free conditions on Matrigel (Corning) coated wells in mTeSR-1 media (StemCell Technologies) supplemented with 100 μg/mL Primo-cin. BU3 was confirmed as mycoplasma free by PCR analysis of gDNA using the following mycoplasma specific primers: 5’ CTT CWT CGA CTT YCA GAC CCA AGG CAT 3’ and 5’ ACA CCA TGG GAG YTG GTA AT 3’ and verified as karyotypically normal as determined by G-band karyotyping analysis from 20 metaphases. iPSC directed differentiation towards the hepatic lineage was performed using a previously published protocol [18,39,40]. Briefly, undifferentiated iPSCs were cultured until confluent and then passaged on Day 0 using gentle cell dissociation reagent (GCDR, StemCell Technologies) to achieve single cell suspensions and replated at 1x10^6 cells per well of a Matrigel coated 6-well plate. Cells were then placed into hypoxic conditions for the remainder of the protocol (5% O2, 5% CO2, 90% N2). Post-passage cells were patterned using the STEMdiff definitive endoderm kit (StemCell Technologies) for 5 days. Day 1 cells were grown in basal media supplemented with STEMdiff Definitive Endoderm Supplements MR and CJ followed by an additional 3 days (Days 2–4) in basal media supplemented with CJ alone. At day 5, endoderm was then passaged with GCDR at a 1:4 ratio onto Matrigel-coated wells and cultured in base complete serum-free differentiation medium (cSFDM) supplemented with growth factors as previously described [18,39,40]. Cells were then cultured for at least an additional 17 days using stage specific growth factors to specify the hepatic lineage and induce maturation.

**Generation of iAT2 air-liquid interface (ALI) culture**

The human iPSC line, SPC2-ST-B2, engineered to carry a tdTomato reporter targeted to the endogenous SFTPC locus [19], underwent directed differentiation to generate iPSC-derived alveolar epithelial type 2 cells (iAT2s) in 3D Matrigel cultures using methods we have previously published [41,42]. Briefly, to establish pure cultures of iAT2s, cells were sorted by flow cytometry to isolate SFTPCtdTomato+ cells on day 41 of differentiation, and subsequently maintained through serial passaging as self-renewing monolayered epithelial spheres by plating in Matrigel (Corning) droplets at a density of 400 cells/μl. The cultures were fed every other day with a defined serum-free distal lung maintenance media composed of base cSFDM supplemented with 3 μM CHIR99021, 10 ng/mL KGF, 50 nM dexamethasone, 0.1 mM cAMP, and 0.1 mM IBMX, referred to as “CK+DCI” media and as described previously [42]. iAT2 culture quality and purity were monitored at each passage by flow cytometry, where > 80% of cells expressing SFTPCtdTomato was observed over time, as shown previously [19,42].

Air-liquid interface (ALI) cultures were generated as previously described [20], with purified iAT2s seeded at 520,000 cells/cm^2 in 6.5 mm Transwell inserts (Corning) coated with
hESC-Qualified Matrigel (Corning) in CK+DCI with 10 \( \mu \)M Rho-associated kinase inhibitor (Sigma Y-27632). At 48h after plating, apical medium is aspirated to initiate air-liquid interface culture, and cultures were fed with CK+DCI basolateral medium every other day prior to experiments.

**Viral sequences**

The following NCBI reference filovirus sequences were used for cloning where indicated and for sequence comparison: Lloviu cuevavirus isolate Lloviu virus/M.schreibersii-wt/ESP/2003/Asturias-Bat86 (GenBank: NC_016144), Zaire ebolavirus isolate Ebola virus/H.sapiens-tc/COD/1976/Yambuku-Mayinga (NC_002549), Reston ebolavirus isolate Reston virus/M.fascicularis-tc/USA/1989/Philippines89-Pennsylvania (NC_004161), and Marburg marburgvirus isolate Marburg virus/H.sapiens-tc/KEN/1980/Mt. Elgon-Musoke (NC_001608).

**Plasmids**

LLOV support plasmids (pCAGGS-NP<sub>LLOV</sub>, -VP35<sub>LLOV</sub>, -VP30<sub>LLOV</sub>, and -L<sub>LLOV</sub>) and 3L5E-Luc minigenome plasmid were described previously [9]. EBOV support plasmids (pCAGGS-NP<sub>EBOV</sub>, -VP35<sub>EBOV</sub>, -VP30<sub>EBOV</sub>, and -L<sub>EBOV</sub>) and RESTV support plasmids (pCAGGS-NP<sub>RESTV</sub>, -VP35<sub>RESTV</sub>, -VP30<sub>RESTV</sub>, and -L<sub>RESTV</sub>) were described previously [9,43]. A plasmid expressing a codon-optimized version of T7 RNA polymerase was synthesized (GeneArt) and the pMIR β-gal plasmid was a kind gift from Matthew Jones, Boston University.

**Cloning of for hybrid trailer minigenomes**

LLOV minigenomes containing hybrid LLOV L 3’ untranslated region (UTR) and trailer appended with sequences from the EBOV trailer were created as follows. A DNA fragment containing the LLOV L 3’ UTR and trailer (nucleotides 18821–18927) appended with the full EBOV L 3’ UTR and trailer (nucleotides 18220–18959) was synthesized (Twist Biosciences) and inserted into the minigenome plasmid 3L5E-Luc [9] via NotI and XmaI digestion and ligation (3L5E<sub>full</sub>-Luc). Truncated versions containing the LLOV L 3’ UTR and trailer appended with the last 48 to 84 nucleotides of the EBOV trailer (Fig 1A) were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs).

**Cloning of bicistronic minigenomes**

A LLOV bicistronic minigenome was generated by cloning a synthesized fragment (Twist Biosciences) containing a short fragment of the LLOV 5’ UTR of the nucleoprotein (NP) gene and 3’ UTR of the polymerase (L) gene flanking firefly and renilla luciferase reporters separated by the VP24-L intergenic region (IR) of LLOV (nucleotides 11866–12229, IR<sub>wt</sub>) into minigenome plasmid 3L5L<sub>full</sub>-Luc using EcoRI and SpeI sites. The IR<sub>wt</sub> version of the LLOV bicistronic minigenome was generated by replacing the wild-type VP24-L IR region in the LLOV IR<sub>wt</sub> bicistronic minigenome with a synthesized fragment containing the VP24-L IR with an insertion spanning overlapping LLOV gene start and end signals (GAAGAATATTAAAGAAAAA) between nucleotides 138 and 139 of the IR (Twist Biosciences) via NEBuilder HiFi DNA Assembly (New England Biolabs).

**Cloning of full-length filovirus plasmids**

The LLOV full-length clones were generated by inserting the viral genome sequence in plasmid p15AK in positive sense orientation under the control of the T7 RNA polymerase.
In this plasmid, the leader region is located immediately downstream of the T7 RNA polymerase promoter and the trailer region is flanked by a hepatitis delta (HdV) ribozyme to generate precise viral genome ends. DNA fragments comprising three portions of the full LLOV genome (NC_016144.1) were synthesized as follows. Fragment 1-LE72 (Twist Biosciences) consisted of a NotI site, a T7 RNA polymerase promoter, nucleotides 1–3 of the EBOV genome, nucleotides 1–4202 of the LLOV genome, a linker sequence to facilitate efficient restriction enzyme digestion (CATCGGGCCCATC), nucleotides 17160–18927 of the LLOV genome including a single silent mutation within the L ORF (A17164T), nucleotides 18887–18958 of the EBOV genome, ending with a portion of the HdV ribozyme SuperCut II (GGGTCGGCATGGCATCTCCACCTCCTC GGCGGTC). Fragment 2 (Twist Biosciences) consisted of nucleotides 4197–11536 of the LLOV genome. Fragment 3 (Twist Biosciences) consisted of nucleotides 11531–17165 of the LLOV genome containing the same silent mutation within the L ORF as Fragment 1. DNA fragments comprising a portion of the LLOV L open reading frame (nucleotides 18447–18820) followed by EBOV (nucleotides 18220–18958, EBOV_{UTR+tr}), or MARV sequences (nucleotides 18477–19111, MARV_{UTR+tr}) and ending with same portion of the HdV ribozyme SuperCutII sequence as used in Fragment 1 were synthesized (Twist Biosciences). A DNA portion of Fragment 2 containing an insertion of the ZsGreen-P2A upstream of the VP40 ORF as described previously [10] was synthesized (Twist Biosciences). Finally, a DNA fragment introducing overlapping gene start and end signals into the intergenic region of the VP24-L IR (GAAGAATATT AAGAAAAA between nucleotides 12001 and 12002, IR_{ins}) was synthesized.

The LLOV-ZsG-IR_{ins}-LE72 version full-length clone was assembled by first cloning Fragment 1-LE72 into the p15AK-EBOV plasmid (kind gift of Hideki Ebihara, Mayo Clinic) [44] via NotI and RsrII digestions and ligation. Fragment 3 was then cloned into p15AK-LLOV-Frag1-LE72 by ApaI and AatII digestions and ligation. Finally, Fragment 2 was cloned into p15AK-LLOV-Frag1-3-LE72 by Xhol and ApaI digestions and ligation. Other trailer versions of the LLOV full-length clone were assembled by first cloning the LLOV L-EBOV_{UTR+tr} and -MARV_{UTR+tr} fragments into the p15AK-LLOV-Frag1 plasmid via SnaBI and RsrlII digestions and ligation. The EBOV_{UTR+tr} and -MARV_{UTR+tr} versions of full-length LLOV clones were assembled by Xhol and AatII digestions and ligation of the backbone portion of the corresponding p15AK-LLOV-Frag1 versions with the Fragment 2+3 portion of the p15AK-LLOV-LE72 full length plasmid. ZsGreen-P2A versions of the full-length clone were cloned by first cloning the ZsGreen-P2A fragment into Fragment 2 via Xhol and Xmal digestions and ligation followed by subsequent replacement of this region within the full-length clone via Xhol and ApaI digestions and ligation. IR_{ins} versions of the full-length clone were cloned by first cloning the IR_{ins} fragment into LLOV-Frag3 via ApaI and PciII digestions and ligation followed by subsequent replacement of this region within the full-length clone via ApaI and AatII digestions and ligation.

For the construction of the EBOV-ZsGreen and RESTV-ZsGreen full-length plasmids, DNA fragments consisting of EBOV nucleotides 2148–5773 and RESTV nucleotides 2555–5287 each with an insert of the ZsGreen-P2A upstream of the VP40 ORF as described previously [10] were synthesized (Twist Biosciences). These fragments were cloned into the p15AK-EBOV [44] and p15AK-RESTV (kind gift of Thomas Hoenen, Friedrich Loeffler Institute) [35] via Sphl or NcoI and Spel, respectively.

Sequences of recombinant viruses generated from this manuscript have been uploaded to GenBank: rLLOV-ZsG-IR_{ins}-EBOV_{UTR+tr} (OL956936), rLLOV-ZsG-IR_{ins}-MARV_{UTR+tr} (OL956937), rLLOV-ZsG-IR_{ins}-LE72 (OL956938), rLLOV-IR_{ins}-MARV_{UTR+tr} (OL956939), rEBOV-ZsG (OL956940), and rRESTV-ZsG (OL956941).
Monocistronic and bicistronic minigenome transfections

LOLV minigenome transfections were performed as described previously [9]. Briefly, 2x10^5 293T or BHK21 cells were seeded in a 12-well plate one day prior to transfection. The next day, cells were transfected with LLOV minigenome plasmid DNA along with LLOV support plasmids encoding NP, VP35, VP30, and L as well as a plasmid expressing codon-optimized T7 RNA polymerase. As negative controls for LLOV minigenome transfections, pCDNA3.1-mCherry plasmid was used instead of L plasmid. When luciferase-expressing minigenomes were used, plasmid pMIR β-gal expressing β-galactosidase was co-expressed to normalize against transfection efficiency. Transfection of 293T cells was performed using TransIT-LT1 per manufacturer’s recommendations (Mirus Bio LLC).

Recombinant filovirus rescue transfections

Recombinant LLOV rescue transfections were performed similar to rescue transfections for other filoviruses Briefly, 1:1 mixtures of Huh7:Vero E6 cells (1x10^5 cells plated per well of a 12-well plate) were transfected with LLOV support plasmids (500 ng pCAGGS-NP_LLOV, 125 ng pCAGGS-VP35_LLOV, 50 ng pCAGGS-VP30_LLOV, and 200 ng pCAGGS-L_LLOV), pCAGGS-T7 (50 ng; codon-optimized), and a full-length plasmid containing the chimeric LLOV genome (1 μg) using TransIT-LT1 per manufacturer’s recommendations (Mirus Bio LLC). Media was changed approximately 18 hours post-transfection and cells were monitored for cytopathic effect (CPE) and fluorescence for ZsGreen-containing clones. Supernatants of cells showing CPE and/or fluorescence were transferred to T75 flasks of Vero E6 cells approximately 7–11 days post-transfection. rEBOV-ZsGreen and rRESTV-ZsGreen clones were rescued similarly, using the corresponding full-length plasmids (1 μg each), pCAGGS-T7 (50 ng; codon-optimized), plus the EBOV (750 ng pCAGGS-NP_EBOV, 125 ng pCAGGS-VP35_EBOV, 50 ng pCAGGS-VP30_EBOV, and 100 ng pCAGGS-L_EBOV) or RESTV (350 ng pCAGGS-NP_RESTV, 125 ng pCAGGS-VP35_RESTV, 50 ng pCAGGS-VP30_RESTV, and 350 ng pCAGGS-L_RESTV) support plasmids, respectively. Rescue of recombinant filoviruses, including LLOV, was performed in BSL-4 facility of the NEIDL following BSL-4 biosafety procedures.

Virus propagation

EBOV Mayinga and RESTV Pennsylvania virus isolates were kindly provided by the NIH NIAID Rocky Mountain laboratories. EBOV, RESTV, and LLOV stocks were grown in Vero E6 cells and purified using ultracentrifugation through a 20% sucrose cushion as previously described [32]. Virus titers were determined in Vero E6 cells by 50% tissue culture infectious dose (TCID_{50}) assay and calculated using the Spearman-Kärber algorithm. All work with EBOV, RESTV, and LLOV was performed under BSL-4 conditions at the NEIDL, following approved SOPs.

Monocistronic minigenome firefly luciferase assays

At 3 days post-transfection, cell lysates were harvested in Reporter Lysis Buffer (Promega) and analyzed with the Luciferase Assay System (Promega) using a LUMIstar Omega luminometer (BMG LabTech). Cell lysates were diluted in 1x Reporter Lysis Buffer as needed. To account for potential differences in transfection efficiency, luciferase values were normalized to β-galactosidase values (Promega). Luciferase values were then calculated as fold increase over the negative control (minus L) values.

Bicistronic minigenome firefly and renilla luciferase assays

At 3 days post-transfection, cell lysates were harvested in Passive Lysis Buffer (Promega) and analyzed with the Dual-Luciferase Reporter Assay System (Promega) using a LUMIstar
Omega luminometer (BMG LabTech). Cell lysates were diluted in 1x Passive Lysis Buffer as needed. To account for potential differences in transfection efficiency, luciferase values were normalized to β-galactosidase values (Promega). Luciferase values were then calculated as fold induction over the negative control (minus L) values.

Proteomic sample preparation and mass spectrometry analysis

For proteomic analysis, SuBK12-08 cells seeded in 6-well plates (1.5x10^6 cells/well) infected with LLOV-ZsG-IR musique-EBOV UTR+tr at an MOI of 1 were lysed 2 days post-infection. The virus was inactivated by resuspending the cell pellets in roughly 5 packed cell volumes (p.c.v) of GuHCl lysis buffer (6 M guanidine hydrochloride, 100 mM Tris pH 8.0, 40 mM chloroacetamide, 10 mM Tris(2-carboxyethyl)phosphine) supplemented with phosphatase inhibitor cocktail (Roche) followed by heating to 100˚C for 10 minutes. Lysates were removed from the BSL-4 laboratory, sonicated with a Branson probe sonicator and were then quantified via Bradford assay. One hundred sixty micrograms of each sample was diluted with 100 mM Tris buffer, pH 8.5 to decrease the GuHCl concentration to 0.75 M. Lysate proteins were then digested by adding trypsin (Pierce) at a 1:50 ratio (enzyme: protein, w/w) and incubated overnight at 37˚C with shaking. Trypsinization was terminated with the addition of trifluoroacetic acid to below pH 3 and the peptide digests were desalted via reversed-phase C18 columns (Sep-pak, Waters) with a wash buffer of 0.1% TFA and elution buffer of 60% acetonitrile. Peptide concentration was determined by a quantitative colorimetric peptide assay (Thermo Fisher), and 1 µg aliquots of clean peptides from each sample were injected sequentially over a nano-flow C18 column (EasySpray, Thermo Fisher) using a EasyNano LC system coupled to an Orbatrap Exploris mass spectrometer (Thermo Fisher) equipped with FAIMS. Data were gathered in a standard data-dependent manner over a 150-minute gradient.

Analysis of raw mass spectrometry data

All acquired MS/MS spectra were simultaneously searched against both a manually curated database of LLOV proteins based on the reference sequence (GenBank: NC_016144) and the complete reviewed and unreviewed proteome for the common bats family (uniprotKB taxonomy Vespertilionidae [9431], downloaded February 9, 2021) using the MaxQuant software (Version 1.6.7.0) that integrates the Andromeda search engine. Briefly, enzyme specificity was set to trypsin (Pierce) at a 1:50 ratio (enzyme: protein, w/w) and incubated overnight at 37˚C with shaking. Cysteine carbamidomethylation was specified as fixed modification whereas oxidation of methionine and N-terminal protein acetylation were set as variable modifications. Precursor ions were searched with a maximum mass deviation of 4.5 ppm and fragment ions with a maximum mass deviation of 20 ppm. Peptide and protein identifications were filtered at 1% FDR using the target-decoy database search strategy [45]. Proteins that could not be differentiated based on MS/MS spectra alone were grouped to protein groups (default MaxQuant settings). A threshold Andromeda score of 40 was applied to peptides. The MaxQuant output file designated “proteinGroups” was used for data normalization.

Transmission electron microscopy of filovirus-infected cells

Huh7 and SuBK12-08 cells seeded on coverslips in 6-well plates were mock-infected or infected with EBOV or LLOV-IR musique-MARV UTR+tr at an MOI of 5. At 1, 2, and 3 dpi, cells were fixed in Karnovsky’s fixative (Electron Microscopy Sciences, EMS) for 6 hours following approved inactivation protocols and removed from the BSL-4 facility. The fixed cells were washed 3 times in 0.1 M cacodylate buffer, postfixed in 1% osmium tetroxide (OsO₄)/1.5% potassium ferrocyanide (K₄[Fe(CN)₆]) for 30 minutes, washed twice in water, incubated in 1%
tannic acid in water for 30 minutes, washed twice in water and once in 50 mM maleate buffer pH 5.15 (MB) followed by a 30-minute incubation in 1% uranyl acetate in MB. The cells were then washed in MB and water and subsequently dehydrated in grades of alcohol (5 minutes each; 50%, 70%, 95%, 2x 100%). Cells were embedded in plastic by inverting a gelatin capsule filled with Epon/Araldite on top of the coverslip and polymerized at 60°C for 24 hours. After polymerization, the coverslip was removed by dipping the block in LN$_2$.

Ultrathin sections (about 80 nm) were cut on a Reichert Ultracut-S microtome, picked up onto copper grids, stained with lead citrate and examined in a JEOL 1200EX Transmission electron microscope. Images were recorded with an AMT 2k CCD camera.

### Transmission electron microscopy and cryoelectron microscopy of filovirus particles

Electron microscopy (EM) and cryo-EM of virion particles were performed as follows. Sucrose cushion-purified stocks of EBOV or LLOV-IR$_{ins}$-MARV$_{UTR+tr}$ were fixed by adding an equal volume of 20% formalin (Fisher Scientific) for at least 6 hours according to approved inactivation procedures. For negatively stained samples, formalin-fixed EBOV or LLOV (4 μl) was applied to the carbon-coated side of the grid and incubated for 3–5 minutes at room temperature. The grid containing virions was then washed on a 0.1 mL drop of Tris buffer (50 mM Tris, pH 7.6) and blotted briefly using filter paper, two times. Grids were then stained on a 5 μl drop of 1% uranyl acetate, blotted briefly, stained again, blotted, and air dried. For cryo-EM, formalin-fixed Ebola or Lloviu virions (1.8 μl) were applied to Quantifoil 2/2 grids, blotted for 7 seconds, and plunge-frozen in liquid ethane using a Vitrobot Mark III. Transmission EM and cryo-EM were performed on an FEI TF20 EM operated at 160 kV and images were recorded on a TVIPS F416 CMOS camera with a pixel size of 1.68–10.09 Å, using the software SerialEM.

### Antiviral drug testing

For small molecule testing, 2x10$^4$ cells/well of HuH7 and SuBK12-08 cells seeded in 96-well plates were pretreated with the indicated amounts of universal interferon (U-IFN, PBL Assay Science) for 18 hours or remdesivir (Selleck Chemicals Ltd), U18666A (Sigma-Aldrich), or DMSO for 30 minutes prior to infection. The cells were then infected with either EBOV-Zs-Green or LLOV-ZsG-IR$_{ins}$-EBOV$_{UTR+tr}$ at an MOI of 1. Fluorescent and brightfield images of infected cells were taken at 2 days post infection. Quantification of fluorescence was performed by subtracting background fluorescence (average intensity of uninfected cells) from the average fluorescence intensity of individual wells. Samples were performed in triplicate.

Viral neutralization assays using mAb114 [29,46,47] (brand name Ebanga; kindly provided by Nancy Sullivan, NIH NIAID Vaccine Research Center) were performed by pre-treating 2x10$^5$ TCID$_{50}$ units of EBOV-ZsGreen or LLOV-ZsG-IR$_{ins}$-EBOV$_{UTR+tr}$ with media alone or media containing 200 ng/mL, 2 μg/mL, or 20 μg/mL mAb114 at 37°C for 1 hour. Following pre-incubation, HuH7 cells were infected with these mixtures, followed by removal of the inocula after 1 hour and replacement with fresh media. Cells were fixed at 2 dpi in 10% formalin (Fisher Scientific) for at least 6 hours. Samples were stained with 4',6-diamidino-2-phenylindole (DAPI; 200 ng/mL and images covering at least 90% of each well’s area at 4x magnification were acquired using a Nikon Ti2 Eclipse microscope and Photometrics Prime BSI camera with NIS Elements AR software. Images were stitched, then imported into QuPath software [48]. Infection rates were determined using the positive cell detection feature in QuPath. Nuclei were detected in the DAPI channel and infected cells were identified by mean fluorescence value in the cytoplasmic region in the green channel.
For cytotoxicity testing, 6x10^4 cells/well of Huh7 and SuBK12-08 cells seeded in 48-well plates were treated with the indicated amounts of universal interferon (U-IFN, PBL Assay Science), remdesivir (Selleck Chemicals Llc), U18666A (Sigma-Aldrich), or DMSO for 2 days. Cell viability was then determined by trypan blue staining using a LUNA-II Automated Cell Counter (Logos Biosystems).

**RNA fluorescence in situ hybridization analysis**

For RNA fluorescent in situ hybridization (FISH) analysis, MDMs seeded in 8-well chamber slides were mock-infected or infected with the indicated viruses at an MOI of 10. Cells were fixed one day post-infection in 10% formalin for at least 6 hours. RNA FISH was performed using the RNAscope Multiplex Fluorescent V2 kit (Advanced Cell Diagnostics). Filovirus RNA was detected using custom-designed probes (Advanced Cell Diagnostics). Specifically, viral mRNA of each filovirus was detected in channel 1 using probes targeting the VP35 transcripts (Advanced Cell Diagnostics) and stained with Opal 520 fluorophore (Perkin-Elmer). Viral genomic RNA was detected in channel 3 using probes targeting the negative-sense genomic sequences of the NP gene (Advanced Cell Diagnostics) and stained with Opal 690 fluorophore (Perkin-Elmer). All FISH probe sets were designed by Advanced Cell Diagnostics and the sequences of these probe sets are proprietary. Staining was performed according to the manufacturer’s protocol for adherent cell samples, with the exception of an additional HRP blocking step following the signal development of the probes detecting viral mRNA as per the manufacturer’s recommendation. Nuclei were stained with kit-supplied DAPI following the manufacturer’s protocol. Coverslips were mounted on slides using FluorSave mounting medium, and slides were subsequently stored at 4˚C prior to imaging. Images were acquired at 20x magnification from sixteen fields of view per well in two replicate wells of each chamber slide using a Nikon Ti2 Eclipse microscope and Photometrics Prime BSI camera with NIS Elements AR software. Total cell number was determined from images using the QuPath cell detection feature to identify nuclei by DAPI staining, and infected cells were manually identified based on the presence of staining for viral mRNA or genomic RNA.

**RNA sample preparation**

Total RNA from 2x10^5 (24-well format) MDMs was isolated at one day post-infection using TRizol reagent (Invitrogen) according to the manufacturer’s protocol. RNA concentration was determined by measuring light absorption at a wavelength of 260 nm using a NanoDrop 1000 spectrophotometer (Thermo Fisher).

**qRT-PCR analysis**

Quantitative reverse transcription-PCR (qRT-PCR) using the QuantiFast SYBR green RT-PCR kit (Qiagen) was performed as described previously [32]. Briefly, five nanograms of mRNA were analyzed by quantitative reverse transcription-PCR (qRT-PCR) using the QuantiFast SYBR green RT-PCR kit (Qiagen). qRT-PCR-based quantification of IL-6, IL-8, IFNB, CXCL10, and β2-microglobulin (B2M) mRNAs were performed using validated QuantiTect primer assays (Qiagen). B2M levels were used as an endogenous control for normalization. qRT-PCR was performed in a CFX96 real-time PCR cycler (Bio-Rad). Fold expression levels compared to those of non-infected control samples were quantified using the threshold cycle (ΔΔCT) method (Bio-Rad CFX Manager 1.5 software) for each donor.
**Viral RNA sequencing**

Total RNA from sucrose cushion-purified viral stocks was isolated using TRIzol-LS reagent (Invitrogen) according to the manufacturer’s protocol. RNA concentration was determined using a NanoDrop 1000 spectrophotometer (Thermo Fisher).

**RNA-Seq**

Sequencing libraries were prepared using the Illumina TruSeq v2 library kit without rRNA depletion or mRNA selection and were sequenced on the Illumina HiSeq 500 to a depth of > 500,000 reads per library. Raw FASTQ files were evaluated for quality using FastQC v0.11.7 [49] followed by alignment to the Vero E6 genome (ChlSab1.1a) using Bowtie2 v2.4.2 [50] with the very-sensitive flag. Reads that did not align to the host genome were passed to Kraken2 v2.0.9 [51] to verify no adventitious agents or other contaminants were present; none were detected. The reads were then aligned to the predicted viral genome using Bowtie2. Viral coverage was assessed with SAMtools v1.10 [52], and single nucleotide variants (SNVs) were called with LoFreq v2.1.3.1 [53]. SNV annotation was performed with Biostrings v2.56.0 [54] and a custom R script.

Sequences of recombinant viruses determined by RNA-Seq have been uploaded to the NCBI under BioProject PRJNA744535 (BioSamples SAMN20109581, SAMN20109582, and SAMN20109583), with individual sets of raw read data uploaded to the Sequence Read Archive: rLLOV-ZsG-IR_{ins}-EBOV_{UTR+tr} (SRR15064796), rLLOV-ZsG-IR_{ins}-MARV_{UTR+tr} (SRR15064794), rLLOV-ZsG-IR_{ins}-LE_{72} (SRR15064795).

**5’-end genomic sequencing with ViBE-Seq**

Viral genomic end sequencing was performed using ViBE-Seq (sequencing of Viral Bonafide Ends), which is a novel method based on the adaptor ligation and cDNA recircularization approaches described previously [55–57]. Briefly, 40 ng of RNA was used as a template for reverse transcription with QIAGEN’s Sensiscript Reverse Transcription Kit according to the manufacturer’s instructions. Specific RT primers were used for cDNA synthesis for each rLLOV-ZsG-IR_{ins}-EBOV_{UTR+tr} (/5Phos/T\footnotesize{\*}A\footnotesize{\*}TGTGAGTCGTTACCTG/iSp18/GGATCC/iSp18/GCTGTAATCTACAAGCA CCTCTT), where \footnotesize{\*} denotes a non-scissile phosphorothioate linkage and iSp18 is an 18-atom hexa-ethyleneglycol spacer. Reverse transcription products were run on a 10% denaturing urea polyacrylamide gel for 2 hours at 10 watts. The gel was then stained with SYBR Gold for 10 minutes and gel portions corresponding to 200 nucleotides (rLLOV-ZsG-IR_{ins}-MARV_{UTR+tr}) or 230 nucleotides (rLLOV-ZsG-IR_{ins}-MARV_{UTR+tr}) were excised. The bottom of a 0.2 mL tube was punctured with a 21 gauge needle. Excised gel bands were extruded via centrifugation through the punctured 0.2 mL tube at 21,000 \( \times \) g for 5 minutes. The pulverized polyacrylamide was resuspended in 0.5 mL of 0.4 M NaCl solution and shaken overnight at 4°C. Polyacrylamide was eliminated from the slurry via centrifugation through a Spin-X centrifuge tube filter (Costar). cDNA was then precipitated by adding 1 \( \mu \)L of Glycoblue Coprecipitant (Thermo Fisher) and 1 volume of 100% isopropanol, overnight incubation at -20°C, and centrifugation at 21,000 \( \times \) g for 1 hour at 4°C. The pellet was washed with 1 \( \mu \)L of 100% ethanol, allowed to air-dry, and resuspended in 20 \( \mu \)L of nuclease-free water. cDNA was quantified using a NanoDrop 1000 spectrophotometer (Thermo Fisher).

Purified cDNA was subject to circularization via CircLigase ssDNA Ligase (Lucigen) per the manufacturer’s specifications. Samples were incubated for 2 hours at 60°C and 10 minutes at 80°C.
PCR reactions to amplify the trailer sequences from the circularized cDNA using Q5 High-Fidelity DNA Polymerase (New England Biolabs) using 60 ng of circularized template were then set up with the following parameters: 98˚C (1 min), [98˚C (10s), 43˚C (30s), 72˚C (12s), repeat 3-5x], [98˚C (10s), 55˚C (30s), 72˚C (12s), repeat 29x], 72˚C (2 min), 4˚C (hold). For each virus, an extended T7 complement forward primer (GCGTCAGTCAGGTAATACGACTACA) was used in combination with a virus-specific reverse primer (TACCTTCTTTACATATTAGCAGACTAGATAATAATCTTCGTGTT for rLLOV-ZsG-IR<ins>-EBOV<sup>UTR+tr</sup> and GCTGTAATCTACAAGCACTCTTTTAAATACATTAGGA for rLLOV-ZsG-IR<ins>-MARV<sup>UTR+tr</sup>). PCR products were run on a 2% agarose gel at 100 V for 1 hour. Bands at 200 nucleotides (rLLOV-ZsG-IR<ins>-EBOV<sup>UTR+tr</sup>) or 230 nucleotides (rLLOV-ZsG-IR<ins>-MARV<sup>UTR+tr</sup>) were excised and purified via Monarch DNA Gel Extraction Kit (New England Biolabs) according to the manufacturer’s instructions. PCR reactions were repeated as necessary to obtain 5–10 ng/μl in 20 μL of nuclease-free water.

Purified PCR products were submitted for sequencing at Mass General Hospital’s Center for Computation and Integrative Biology DNA Core in Cambridge, MA. Data are provided as S1 Dataset.

Statistics
Luciferase assays and drug testing: Standard error of the mean (SEM) and two-tailed t-tests for all figures were calculated using GraphPad Prism software.

Supporting information
S1 Fig. Supplementary figure to Fig 1B: Luciferase-based minigenome assays comparing the 3L5E and chimeric 3L5LE<sub>X</sub> minigenomes with or without L. Mean firefly luciferase activity normalized to β-galactosidase activity (transfection control) with standard deviation is shown.
(TIF)

S2 Fig. Recombinant Lloviu virus (rLLOV<sub>comp</sub>) clones used in this study. Schematics and names of full-length clones of rLLOV<sub>comp</sub> that were rescued (above) and those that were not (below). Noncoding regions are indicated in light gray, LLOV genes are in gray, a ZsGreen-P2A reporter (ZsG) is in light green followed by a dark gray bar, gene start and end signals are black bars within noncoding regions, red bars indicate the IR<ins>ins</ins> insertion in the VP24-L intergenic region, dark green indicates the Ebola virus (EBOV) L 3′ UTR and trailer (EBOV<sup>UTR+tr</sup>), dark blue indicates the Marburg virus L 3′ UTR and trailer (MARV<sup>UTR+tr</sup>), and pink indicates the last 72 nucleotides of the EBOV trailer (LE<sub>72</sub>). rLLOV<sub>comp</sub> clones are to scale with the exception of the T7 RNA polymerase promoter (P<sub>T7</sub>), hepatitis delta virus ribozyme (Rib<sub>HDV</sub>), and T7 RNA polymerase terminator sequences (T<sub>T7</sub>) which are enlarged for clarity. Scale bar above indicates 1 kb increments, starting with the first nucleotide of the rLLOV<sub>comp</sub> clones. Important restriction enzymes that were used to clone full-length rLLOV<sub>comp</sub> plasmids are indicated above, including an AatII site which introduces a silent mutation within L (A17949T for the rLLOV-ZsG-IR<ins>-EBOV<sup>UTR+tr</sup>, clone, corresponding to nucleotide 17164 of the published LLOV sequence, NCBI Reference Sequence NC_016144).
(TIF)

S3 Fig. Growth curve of rEBOV, rRESTV, and the indicated versions of rLLOV<sub>comp</sub> using an initial MOI of 0.01 in SuBK12 08 (A) and Huh7 cells (B).
(TIF)
S4 Fig. Density plot of all proteins identified by mass spectrometry of SuBK12-08 cells infected with LLOV-ZsG-IRins-EBOVUTR+tr (rLLOVcomp). (A) Kernel density plot indicating the distribution of the number of identified peptides per protein across all 3,939 identified proteins within the rLLOVcomp-infected SuBK12-08 samples described in Fig 2E. The plot is annotated with the location of all viral proteins within the distribution. (B) Table of rLLOVcomp-encoded proteins and the number of peptides detected by mass spectrometry.

(TIF)

S5 Fig. EBOV-infected cells and virions. Huh7 cells were infected with EBOV at an MOI of 5 and fixed at 2 dpi. (A) Thin section of EBOV-infected cell releasing viral particles. (B) Thin section shows virus budding; inset shown on the right is magnified 3x; protein is black. (C) Circled area indicates EBOV inclusions containing cross sectioned and longitudinal sectioned nucleocapsids. (D) Negatively stained, isolated EBOV virions show heterogeneous ultrastructure, including 6-shaped, filamentous, shepherd’s hook, and branched filamentous structures, as seen previously [58]; protein is white.

(TIF)

S6 Fig. RNA-Seq data from rLLOVcomp clones. (A) Total RNA sequencing of passage 2 rLLOVcomp stocks yielded viral genome coverage $\geq 100x$ with the exception of the leader and trailer regions. Single nucleotide variable (SNV) plot (B) and Table (C), indicating the abundance and location within the genome of SNVs (SNVs $\geq 10\%$ included in the Table). Few consensus SNVs ($>50\%$) were observed, whereas multiple subconsensus SNVs were observed at 10–20%. Mutations within the reporter gene (ZsGreen-P2A) are indicated in green.

(TIF)

S7 Fig. Sequence coverage and divergence of rLLOVcomp 5’ genome ends. Sequence coverage of the trailer region of both (A) rLLOV-ZsG-IRins-EBOVUTR+tr and (B) rLLOV-ZsG-IRins-MARVUTR+tr virus stocks. Sequencing coverage percentages were calculated from the number of reads mapping to individual nucleotides within the respective viral genomes. Divergence from the EBOV trailer or MARV trailer sequences are plotted in red and highlighted with a black arrow. Sequencing results captured the terminal 175 nucleotides of the rLLOV-ZsG-IRins-EBOVUTR+tr sequence and the terminal 230 nucleotides of the rLLOV-ZsG-IRins-MARVUTR+tr sequence. Very few differences were observed between the rLLOVcomp full-length clone sequences and the viral stocks (passage 2). Very low abundance differences identified in the rLLOV-ZsG-IRins-EBOVUTR+tr stock include a deletion (position 20200, found in 0.58% of reads), an A insertion (between nucleotides 20308 and 20309, 0.33% of reads and the cause of the observed large dip in the graph due to its low abundance), a U to A mutation (position 20325, 0.3% of reads), and a U deletion (position 20337, 0.24% of reads) all in distinct, truncated species with very low read abundance. A significant portion of the reads (22.21% of reads) contained a terminal AC dinucleotide which is not present within the corresponding full-length clone. Similar to the data for the rLLOV-ZsG-IRins-EBOVUTR+tr stock, there are few differences noted between the rLLOV-ZsG-IRins-MARVUTR+tr sequence and corresponding rLLOVcomp full-length clone. The only low abundance difference observed was a single A deletion (position 20309, 2.35% of reads). There were no terminal nucleotide additions present in any of the rLLOV-ZsG-IRins-MARVUTR+tr sequence reads.

(TIF)

S8 Fig. Supplementary figure to Fig 5A–5C: Cytotoxicity data from tested antiviral compounds. Huh7 and SuBK12-08 cells were treated as indicated for 2 days and cell viability was determined by trypan blue staining.

(TIF)
S9 Fig. Supplementary figure to Fig 6: Uninfected mock controls for the RNA FISH data shown in Fig 6. Human monocyte-derived macrophages (MDMs) were left uninfected, fixed at 1 dpi, and analyzed for the presence of negative (genome, magenta, in top row) and positive (mRNA and antigenome, green, in middle row) sense viral RNA using the indicated probe sets by RNA FISH. Cells were co-stained with DAPI (shown with merged channels, in bottom row). Indicated size bar is the same for all images.

(TIF)

S10 Fig. Supplementary figure to Fig 6: RNA FISH analysis of human monocyte-derived macrophages (MDMs) infected with EBOV, RESTV, or rLLOV. MDMs derived from donor 1 were infected at an MOI of 10 with EBOV, RESTV, or rLLOV-IRins-MARVUTR+tr. At 1 dpi, cells were fixed and analyzed for the presence of negative (genome, magenta, in top row) and positive (mRNA and antigenome, green, in middle row) sense viral RNA by RNA FISH. Cells were co-stained with DAPI (shown with merged channels, in bottom row). Images are shown with increased brightness in green and magenta channels to clearly visualize lower-intensity staining observed in rLLOV-IRins-MARVUTR+tr-infected cells. Indicated size bar is the same for all images.

(TIF)

S1 Dataset. Viral genome end sequence data was derived from plain text files generated from CRISPR amplicon Next-generation sequencing. The attached files contain a list of unique sequence contigs synthesized from the overlap of two reads (forward and reverse) generated during the sequencing process. The list contains the contigs in order from highest abundance to lowest abundance in the samples provided. Furthermore, each unique contig comes with the number of pairs of NGS reads which make up each contig. This sequencing was performed on gel-extracted dsDNA PCR products by the Mass General Hospital Center for Computational and Integrative Biology (CCIB) DNA Core.

(ZIP)

Acknowledgments
The authors wish to thank Thomas Hoenen and Hideki Ebihara for sharing recombinant wild-type EBOV and RESTV cDNA clones, Nancy Sullivan for donation of antibody mAB114, Ayato Takada for sharing SuBK12-08 cells, Apath L.L.C. for sharing Huh7 cells, Matthew Jones for sharing plasmid pMIR-β-gal, and the National Institutes of Health (NIH) Rocky Mountain Laboratories for providing EBOV and RESTV stocks.

Author Contributions
Conceptualization: Adam J. Hume, Elke Mühlberger.

Data curation: Jacquelyn Turcinovic.

Formal analysis: Adam J. Hume, Jacquelyn Turcinovic.

Funding acquisition: Ellen L. Suder, Esther Bullitt, Darrell N. Kotton, Gabor Kemenesi, Daniel Cifuentes, Elke Mühlberger.

Investigation: Adam J. Hume, Baylee Heiden, Judith Olejnik, Ellen L. Suder, Stephen Ross, Whitney A. Scoon, Esther Bullitt, Maria Ericsson, Mitchell R. White, Jacquelyn Turcinovic, Tran T. N. Thao, Ryan M. Hekman, Joseph E. Kaserman, Jessie Huang, Konstantinos-Dionysios Alysandratos.
Methodology: Adam J. Hume, Elke Mühlberger.

Project administration: Adam J. Hume, Elke Mühlberger.

Resources: Gabor E. Toth, Ferenc Jakab, Volker Thiel, Gabor Kemenesi.

Software: Jacquelyn Turcinovic.

Supervision: Adam J. Hume, Elke Mühlberger.

Validation: Adam J. Hume, Baylee Heiden, Judith Olejnik, Ellen L. Suder, Elke Mühlberger.

Visualization: Adam J. Hume, Judith Olejnik, Ellen L. Suder, Stephen Ross, Esther Bullitt, Maria Ericsson, Jacquelyn Turcinovic.

Writing – original draft: Adam J. Hume.

Writing – review & editing: Adam J. Hume, Judith Olejnik, Ellen L. Suder, Stephen Ross, Jacquelyn Turcinovic, Tran T. N. Thao, Ryan M. Hekman, Joseph E. Kaserman, Konstantinos-Dionysios Alysandratos, Darrell N. Kotton, Andrew A. Wilson, Andrew Emili, Volker Thiel, John H. Connor, Gabor Kemenesi, Daniel Cifuentes, Elke Mühlberger.

References

1. Letko M, Seifert SN, Olival KJ, Plowright RK, Munster VJ. Bat-borne virus diversity, spillover and emergence. Nat Rev Microbiol. 2020; 18(8):461–71. Epub 2020/06/13. https://doi.org/10.1038/s41579-020-0394-z PMID: 32528128; PubMed Central PMCID: PMC7289071.

2. Negredo A, Palacios G, Vazquez-Moron S, Gonzalez F, Dopazo H, Molero F, et al. Discovery of an ebolavirus-like filovirus in europe. PLoS Pathog. 2011; 7(10):e1002304. Epub 2011/11/01. https://doi.org/10.1371/journal.ppat.1002304 PPATHOGENS-D-11-01432 [pii]. PMID: 22039362; PubMed Central PMCID: PMC3197594.

3. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018; 3(10):1084–9. https://doi.org/10.1038/s41564-018-0227-2 PMID: 30150734.

4. Yang XL, Tan CW, Anderson DE, Jiang RD, Li B, Zhang W, et al. Characterization of a filovirus (Mengla virus) from Rousettus bats in China. Nat Microbiol. 2019. https://doi.org/10.1038/s41564-018-0328-y PMID: 30617348.

5. Kemenesi G, Kurucz K, Dallos B, Zana B, Foldes F, Boldogh S, et al. Re-emergence of Lloviu virus in Miniopterus schreibersii bats, Hungary, 2016. Emerg Microbes Infect. 2018; 7(1):66. https://doi.org/10.1038/s41426-018-0067-4 PMID: 29670087; PubMed Central PMCID: PMC5906664.

6. Ramirez de Arellano E, Sanchez-Lockhart M, Perteguer MJ, Bartlett M, Ortiz M, Campioli P, et al. First Evidence of Antibodies Against Lloviu Virus in Schreiber’s Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain. Viruses. 2019; 11(4). Epub 2019/04/24. https://doi.org/10.3390/v11040360 PMID: 31050734.

7. Amarasinghe GK, Ayllon MA, Bao Y, Basler CF, Bavari S, Blasdell KR, et al. Taxonomy of the order Mononegavirales: update 2019. Arch Virol. 2019; 164(7):1967–80. Epub 2019/05/16. https://doi.org/10.1007/s00705-019-04247-4 PMID: 31099928; PubMed Central PMCID: PMC6641539.

8. Liu X, Speranza E, Munoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival I, et al. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 2017; 18(1):4. https://doi.org/10.1186/s13059-016-1137-3 PMID: 28100256; PubMed Central PMCID: PMC5244546.

9. Manhart WA, Pacheco JR, Hume AJ, Cresseyn TN, Deflube LR, Muhlberger E. A Chimeric Lloviu Virus Minigenome System Reveals that the Bat-Derived Filovirus Replicates More Similarly to Ebolaviruses than Marburgviruses. Cell Rep. 2018; 24(10):2573–80 e4. https://doi.org/10.1016/j.celrep.2018.08.008 PMID: 30184492; PubMed Central PMCID: PMC6159894.

10. Albarino CG, Wigginton Guerrero L, Lo MK, Nichol ST, Towner JS. Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein. Virology. 2015; 484:259–64. Epub 2015/07/01. https://doi.org/10.1016/j.virology.2015.06.013 PMID: 26122472.

11. Whelan SP, Barr JN, Wertz GW. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol. 2004; 283:61–119. https://doi.org/10.1007/978-3-662-06099-5_3 PMID: 15298168.
12. Schneemann A, Schneider PA, Lamb RA, Lipkin WI. The remarkable coding strategy of borna disease virus: a new member of the nonsegmented negative strand RNA viruses. Virology. 1995; 210(1):1–8. Epub 1995/06/20. https://doi.org/10.1006/viro.1995.1311 PMID: 7793061.

13. Takadate Y, Manzoor R, Saito T, Kida Y, Maruyama J, Kondoh T, et al. Receptor-Mediated Host Cell Preference of a Bat-Derived Filovirus, Lloviu Virus. Microorganisms. 2020; 8(10). Epub 2020/10/09. https://doi.org/10.3390/microorganisms8101530 PMID: 33027954; PubMed Central PMCID: PMC7601172.

14. Shabman RS, Jabado OJ, Mire CE, Stockwell TB, Edwards M, Mahajan M, et al. Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells. MBio. 2014; 5(6):e02011. Epub 2014/11/06. https://doi.org/10.1128/mBio.02011-14 PMID: 25370495; PubMed Central PMCID: PMC4222107.

15. Kolesnikova L, Nanbo A, Becker S, Kawaoka Y. Inside the Cell: Assembly of Filoviruses. Curr Top Microbiol Immunol. 2017; 411:353–80. https://doi.org/10.1007/978_2017_15 PMID: 28601948.

16. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. 2015; 13(11):663–76. Epub 2015/10/07. https://doi.org/10.1038/nrmicro3524 PMID: 26439085; PubMed Central PMCID: PMC4520123.

17. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015; 235(2):153–74. Epub 2014/10/10. https://doi.org/10.1002/path.4456 PMID: 25297522; PubMed Central PMCID: PMC7663960.

18. Kaserman JE, Hurley K, Dodge M, Villacorta-Martin C, Vedaie M, Jean JC, et al. A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells. Stem Cell Reports. 2020; 15(1):242–55. Epub 2020/07/04. https://doi.org/10.1016/j.stemcr.2020.06.006 PMID: 32619491; PubMed Central PMCID: PMC7600949.

19. Hurley K, Ding J, Villacorta-Martin C, Herriges MJ, Jacob A, Vedaie M, et al. Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors. Cell Stem Cell. 2020; 26(4):583–608 e6. Epub 2020/02/01. https://doi.org/10.1016/j.stem.2019.12.009 PMID: 32004478; PubMed Central PMCID: PMC7469703.

20. Huang J, Hume AJ, Abe KO, Werder RB, Villacorta-Martin C, Alysandratos KD, et al. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell. 2020. Epub 2020/09/27. https://doi.org/10.1016/j.stem.2020.09.013 PMID: 32973216; PubMed Central PMCID: PMC7560049.

21. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 2011; 13(11):939–6. Epub 2011/06/10. https://doi.org/10.1016/j.micinf.2011.05.002 PMID: 21651988.

22. Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, Smith G, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis. 2011; 204(2):200–8. Epub 2011/05/17. https://doi.org/10.1093/infdis/jir077 PMID: 21571728.

23. Haddock E, Saturday G, Feldmann F, Hanley PW, Okumura A, Lovaglio J, et al. Reston virus causes severe respiratory disease in young domestic pigs. Proc Natl Acad Sci U S A. 2021; 118(2). Epub 2021/01/06. https://doi.org/10.1073/pnas.2015657118 PMID: 33443212; PubMed Central PMCID: PMC7812766.

24. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016; 531(7594):381–5. Epub 2016/03/05. https://doi.org/10.1038/nature17180 PMID: 26934220.

25. Bodmer BS, Zierke L, Wendt L, Gressler J, Groseth A, Hoenen T. Remdesivir inhibits the polymerases of the novel filoviruses Lloviu and Bombali virus. Antiviral Res. 2021; 192:105120. Epub 2021/05/17. https://doi.org/10.1016/j.antiviral.2021.105120 PMID: 34126139.

26. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011; 477(7364):340–3. Epub 2011/08/05. https://doi.org/10.1038/nature10348 PMID: 21866103; PubMed Central PMCID: PMC3175325.

27. Shoemaker CJ, Schomberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, et al. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One. 2013; 8(2):e56265. Epub 2013/02/27. https://doi.org/10.1371/journal.pone.0056265 PONE-D-12-34225 [pii]. PMID: 23441171; PubMed Central PMCID: PMC3575416.

28. Ng M, Ndungo E, Jangra RK, Cai Y, Postnikova E, Radoshitzky SR, et al. Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1. Virology. 2014; 468–470:637–46. https://doi.org/10.1016/j.virology.2014.08.019 PMID: 25310500; PubMed Central PMCID: PMC4252868.
29. Misasi J, Gilman MS, Kanekiyoi M, Gui M, Cagigi A, Mulangu S, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016; 351(6279):1343–6. Epub 2016/02/27. https://doi.org/10.1126/science.aad6117 PMID: 26917592.

30. Wec AZ, Herbert AS, Murin CD, Nyakatare KU, Abelson DM, Fels JM, et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebola Viruses. Cell. 2017; 169(5):878–90 e15. Epub 2017/05/20. https://doi.org/10.1016/j.cell.2017.04.037 PMID: 28525755; PubMed Central PMCID: PMC5808922.

31. Kotliar D, Lin AE, Logue J, Hughes TK, Khoury NM, Rajh SS, et al. Single-Cell Profiling of Ebola Virus Disease In Vivo Reveals Viral and Host Dynamics. Cell. 2020. Epub 2020/09/02. https://doi.org/10.1016/j.cell.2020.08.002 PMID: 32159858.

32. Olejnik J, Forero A, Deflube LR, Hume AJ, Manhart WA, Nishida A, et al. Ebola Viruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages. J Virol. 2017; 91(11). https://doi.org/10.1128/JVI.00179-17 PMID: 28331091; PubMed Central PMCID: PMC5432386.

33. Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol. 1999; 235:97–116. Epub 1999/01/20. https://doi.org/10.1007/3-642-59949-1_7 PMID: 9893381; PubMed Central PMCID: PMC.

34. Bodmer BS, Gressier J, Schmidt ML, Holzerland J, Brandt J, Braun S, et al. Differences in Viral RNA Synthesis but Not Budding or Entry Contribute to the In Vitro Attenuation of Reston Virus Compared to Ebola Virus. Microorganisms. 2020; 8(8). Epub 2020/08/17. https://doi.org/10.3390/microorganisms8081215 PMID: 32796523; PubMed Central PMCID: PMC7463789.

35. Groseth A, Marzi A, Hoenen T, Herwig A, Gardner D, Becker S, et al. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog. 2012; 8(8):e1002847. Epub 2012/08/27. https://doi.org/10.1371/journal.ppat.1002847 PMID: 22876185; PubMed Central PMCID: 21987747.

36. Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011; 204 Suppl 3:S757–60. Epub 2011/10/19. https://doi.org/10.1093/infdis/jir296 PubMed Central PMCID: PMC3410888.

37. Misasi J, Gilman MS, Kanekiyoi M, Gui M, Cagigi A, Mulangu S, et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science. 2016; 351(6279):1343–6. Epub 2016/02/27. https://doi.org/10.1126/science.aad6117 PMID: 26917592.

38. Kurmann AA, Serra M, Hawkins F, Rankin SA, Mori M, Astapova I, et al. Renal Interferon Inhibitory Domain. J Virol. 2009; 83(17):8993–109. https://doi.org/10.1128/JVI.02265-13 PMID: 24131712; PubMed Central PMCID: PMC3911722.

39. Jacob A, Morley M, Hawkins F, McCauley KB, Jeon JC, Heins H, et al. Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. Cell Stem Cell. 2017; 21(4):472–88 e10. Epub 2017/10/03. https://doi.org/10.1016/j.stem.2017.08.014 PMID: 28965766; PubMed Central PMCID: PMC5755562.

40. Jacob A, Vedai M, Roberts DA, Thomas DC, Villacorta-Martin C, Alyasrdratos KD, et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat Protoc. 2019; 14(12):3303–32. Epub 2019/11/17. https://doi.org/10.1038/s41596-019-0220-0 PMID: 31732721; PubMed Central PMCID: PMC7252494.

41. Jacob A, Morley M, Hawkins F, McCauley KB, Jean JC, Heins H, et al. Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. Cell Stem Cell. 2017; 21(4):472–88 e10. Epub 2017/10/03. https://doi.org/10.1016/j.stem.2017.08.014 PMID: 28965766; PubMed Central PMCID: PMC5755562.

42. Jacob A, Vedai M, Roberts DA, Thomas DC, Villacorta-Martin C, Alyasrdratos KD, et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat Protoc. 2019; 14(12):3303–32. Epub 2019/11/17. https://doi.org/10.1038/s41596-019-0220-0 PMID: 31732721; PubMed Central PMCID: PMC7252494.

43. Schürmann M, Gantke T, Mühlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol. 2009; 83(17):8993–7. Epub 2009/06/12. JVI.00523-09 [pii] PMID: 19515768; PubMed Central PMCID: PMC4437473.

44. Kaserman KE, Wilson AA. Protocol for Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) into a Hepatic Lineage. Methods Mol Biol. 2017; 1639:151–60. Epub 2017/07/29. https://doi.org/10.1007/978-1-4939-7163-3_15 PMID: 28752455; PubMed Central PMCID: PMC7525494.

45. Jacob A, Morley M, Hawkins F, McCauley KB, Jean JC, Heins H, et al. Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells. Cell Stem Cell. 2017; 21(4):472–88 e10. Epub 2017/10/03. https://doi.org/10.1016/j.stem.2017.08.014 PMID: 28965766; PubMed Central PMCID: PMC5755562.

46. Jacob A, Vedai M, Roberts DA, Thomas DC, Villacorta-Martin C, Alyasrdratos KD, et al. Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells. Nat Protoc. 2019; 14(12):3303–32. Epub 2019/11/17. https://doi.org/10.1038/s41596-019-0220-0 PMID: 31732721; PubMed Central PMCID: PMC7252494.

47. Schürmann M, Gantke T, Mühlberger E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol. 2009; 83(17):8993–7. Epub 2009/06/12. JVI.00523-09 [pii] PMID: 19515768; PubMed Central PMCID: PMC4437473.

48. Tsuda Y, Hoenen T, Banadyga L, Weisend C, Ricklefs SM, Porcella SF, et al. An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity. J Infect Dis. 2015; 212 Suppl 2:S129–37. Epub 2015/03/27. https://doi.org/10.1093/infdis/jiu681 PMID: 25810440; PubMed Central PMCID: PMC4564527.

49. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4(3):207–14. Epub 2007/03/01. https://doi.org/10.1038/nmeth1019 PMID: 17327847.
46. Corti D, Misasi J, Mulangu S, Stanley DA, Kanekiyo M, Wollen S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016; 351(6279):1339–42. Epub 2016/02/27. https://doi.org/10.1126/science.aad5224 PMID: 26917593.

47. Lee A. Ansuvimab: First Approval. Drugs. 2021; 81(5):595–8. Epub 2021/03/23. https://doi.org/10.1007/s40265-021-01483-4 PMID: 33751448; PubMed Central PMCID: PMC7983082.

48. Bankhead P, Loughey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017; 7(1):16878. Epub 2017/12/06. https://doi.org/10.1038/s41598-017-17204-5 PMID: 29203879; PubMed Central PMCID: PMC5715110.

49. Andrews S. FastQC: A Quality Control Tool for High Throughput Sequencing Data. 2015.

50. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9(4):357–9. Epub 2012/03/06. https://doi.org/10.1038/nmeth.1923 PMID: 22388286; PubMed Central PMCID: PMC3322381.

51. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019; 20(1):257. Epub 2019/11/30. https://doi.org/10.1186/s13059-019-1891-0 PMID: 31779668; PubMed Central PMCID: PMC6683579.

52. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078–9. Epub 2009/06/10. https://doi.org/10.1093/bioinformatics/btp352 PMID: 19505943; PubMed Central PMCID: PMC2723002.

53. Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012; 40(22):11189–201. Epub 2012/10/16. https://doi.org/10.1093/nar/gks918 PMID: 23066108; PubMed Central PMCID: PMC3526318.

54. Pagès H, Aboyoun R, Gentleman R, DebRoy S. Biostriangs: Efficient manipulation of biological strings. R package version 2560. 2020.

55. Huppertz I, Attig J, D’Ambrogio A, Easton LE, Sibley CR, Sugimoto Y, et al. CLIP: protein-RNA interactions at nucleotide resolution. Methods. 2014; 65(3):274–87. Epub 2013/11/05. https://doi.org/10.1016/j.ymeth.2013.10.011 PMID: 24184352; PubMed Central PMCID: PMC3988997.

56. McGlincy NJ, Ingolia NT. Transcriptome-wide measurement of translation by ribosome profiling. Methods. 2017; 126:112–29. Epub 2017/06/06. https://doi.org/10.1016/j.ymeth.2017.05.028 PMID: 28379404; PubMed Central PMCID: PMC5582988.

57. Kretov DA, Walawalkar IA, Mora-Martin A, Shafik AM, Moxon S, Cifuentes D. Ago2-Dependent Processing Allows miR-451 to Evade the Global MicroRNA Turnover Elicited during Erythropoiesis. Mol Cell. 2020; 78(2):317–28 e6. Epub 2020/03/20. https://doi.org/10.1016/j.molcel.2020.02.020 PMID: 32191872; PubMed Central PMCID: PMC7201373.

58. Ellis DS, Stamford S, Lloyd G, Bowen ET, Platt GS, Way H, et al. Ebola and Marburg viruses: I. Some ultrastructural differences between strains when grown in Vero cells. J Med Virol. 1979; 4(3):201–11. https://doi.org/10.1002/jmv.1890040306 PMID: 94087